 Connection
David Simpson to Botulinum Toxins, Type A
This is a "connection" page, showing publications David Simpson has written about Botulinum Toxins, Type A.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
7.080 |
|
|
|
-
Wissel J, Cam?es-Barbosa A, Comes G, Althaus M, Scheschonka A, Simpson DM. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021 Dec 11; 13(12).
Score: 0.750
-
Jog M, Lee J, Scheschonka A, Chen R, Ismail F, Boulias C, Hobson D, King D, Althaus M, Simon O, Dersch H, Frucht S, Simpson DM. Tolerability and Efficacy of Customized IncobotulinumtoxinA Injections for Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Study. Toxins (Basel). 2020 Dec 20; 12(12).
Score: 0.701
-
Bensmail D, Wissel J, Laffont I, Simon O, Scheschonka A, Flatau-Baqu? B, Dressler D, Simpson DM. Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. Ann Phys Rehabil Med. 2021 Mar; 64(2):101376.
Score: 0.668
-
Wissel J, Bensmail D, Scheschonka A, Flatau-Baqu? B, Simon O, Althaus M, Simpson DM. Post hoc analysis of the improvement in shoulder spasticity and safety observed following treatment with incobotulinumtoxinA. J Rehabil Med. 2020 Mar 18; 52(3):jrm00028.
Score: 0.665
-
Fheodoroff K, Rekand T, Medeiros L, Ko?mehl P, Wissel J, Bensmail D, Scheschonka A, Flatau-Baqu? B, Simon O, Dressler D, Simpson DM. Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. Health Qual Life Outcomes. 2020 Mar 04; 18(1):51.
Score: 0.664
-
Turner-Stokes L, Ashford S, Esquenazi A, Wissel J, Ward AB, Francisco G, Lains J, Suputtitada A, Serrano S, Baguley IJ, Barnes M, Simpson DM. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework. Eur J Phys Rehabil Med. 2018 Aug; 54(4):605-617.
Score: 0.570
-
Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Graham GD, McGuire JR, Odderson IR, Patel AT, Simpson DM. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a?Delphi Panel Approach. PM R. 2017 Oct; 9(10):960-968.
Score: 0.539
-
Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I. OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process. PM R. 2017 02; 9(2):136-148.
Score: 0.514
-
Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10; 86(19):1818-26.
Score: 0.507
-
Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve. 2012 Sep; 46(3):443-8.
Score: 0.394
-
Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009 Jan; 90(1):9-16.e2.
Score: 0.306
-
O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM. Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study. PM R. 2018 01; 10(1):1-10.
Score: 0.137
-
Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqu? B, Simon O, Rochford ET, Dressler D, Simpson DM. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017 Apr 04; 88(14):1321-1328.
Score: 0.135
-
Jost WH, Benecke R, Hauschke D, Jankovic J, Kanovsk? P, Roggenk?mper P, Simpson DM, Comella CL. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26.
Score: 0.118
-
Gracies JM, Bayle N, Goldberg S, Simpson DM. Botulinum toxin type B in the spastic arm: a randomized, double-blind, placebo-controlled, preliminary study. Arch Phys Med Rehabil. 2014 Jul; 95(7):1303-11.
Score: 0.110
-
Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
Score: 0.102
-
Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013 Jun 01; 67:115-28.
Score: 0.100
-
Vinti M, Costantino F, Bayle N, Simpson DM, Weisz DJ, Gracies JM. Spastic cocontraction in hemiparesis: effects of botulinum toxin. Muscle Nerve. 2012 Dec; 46(6):926-31.
Score: 0.099
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|